Blocking Interaction of Viral Gp120 and CD4-expressing T Cells by Single-stranded DNA Aptamers

Overview

Journal Int J Biochem Cell Biol

Publisher Elsevier

Specialties Biochemistry
Cell Biology

Date 2014 Mar 26

PMID 24661998

Citations 5

Authors

Nianxi Zhao

Sung-Nan Pei

Parag Parekh

Eric Salazar

Youli Zu

Affiliations

Soon will be listed here.

Abstract

To investigate the potential clinical application of aptamers to prevention of HIV infection, single-stranded DNA (ssDNA) aptamers specific for CD4 were developed using the systematic evolution of ligands by exponential enrichment approach and next generation sequencing. In contrast to RNA-based aptamers, the developed ssDNA aptamers were stable in human serum up to 12h. Cell binding assays revealed that the aptamers specifically targeted CD4-expressing cells with high binding affinity (Kd=1.59nM), a concentration within the range required for therapeutic application. Importantly, the aptamers selectively bound CD4 on human cells and disrupted the interaction of viral gp120 to CD4 receptors, which is a prerequisite step of HIV-1 infection. Functional studies showed that the aptamer polymers significantly blocked binding of viral gp120 to CD4-expressing cells by up to 70% inhibition. These findings provide a new approach to prevent HIV-1 transmission using oligonucleotide aptamers.

Citing Articles

Aptamers in Virology-A Consolidated Review of the Most Recent Advancements in Diagnosis and Therapy.

Yadavalli T, Volety I, Shukla D Pharmaceutics. 2021; 13(10).

PMID: 34683938 PMC: 8540715. DOI: 10.3390/pharmaceutics13101646.

Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor.

Zhang C, Zhang H, Huang L, Zhu S, Xu Y, Zhang X Molecules. 2018; 23(11).

PMID: 30463393 PMC: 6278378. DOI: 10.3390/molecules23113036.

Aptamers in HIV research diagnosis and therapy.

Bala J, Chinnapaiyan S, Kumar Dutta R, Unwalla H RNA Biol. 2018; 15(3):327-337.

PMID: 29431588 PMC: 5927724. DOI: 10.1080/15476286.2017.1414131.

Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.

Nozari A, Berezovski M Mol Ther Nucleic Acids. 2017; 6:29-44.

PMID: 28325295 PMC: 5363458. DOI: 10.1016/j.omtn.2016.12.002.

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.

Zhao N, Pei S, Qi J, Zeng Z, Iyer S, Lin P Biomaterials. 2015; 67:42-51.

PMID: 26204224 PMC: 4550516. DOI: 10.1016/j.biomaterials.2015.07.025.

References

Horn W, Convery M, Stonehouse N, Adams C, Liljas L, Phillips S . The crystal structure of a high affinity RNA stem-loop complexed with the bacteriophage MS2 capsid: further challenges in the modeling of ligand-RNA interactions. RNA. 2004; 10(11):1776-82. PMC: 1370665. DOI: 10.1261/rna.7710304. View

Holtz C, Mansky L . Variation of HIV-1 mutation spectra among cell types. J Virol. 2013; 87(9):5296-9. PMC: 3624292. DOI: 10.1128/JVI.03576-12. View

Andrieux-Meyer I, Calmy A, Cahn P, Clayden P, Raguin G, Katlama C . Preferred antiretroviral drugs for the next decade of scale up. J Int AIDS Soc. 2012; 15(2):17986. PMC: 3494169. DOI: 10.7448/IAS.15.2.17986. View

Song K, Lee S, Ban C . Aptamers and their biological applications. Sensors (Basel). 2012; 12(1):612-31. PMC: 3279232. DOI: 10.3390/s120100612. View

Tombelli S, Mascini M . Aptamers biosensors for pharmaceutical compounds. Comb Chem High Throughput Screen. 2010; 13(7):641-9. DOI: 10.2174/1386207311004070641. View

Wang T, Ray J . Aptamer-based molecular imaging. Protein Cell. 2012; 3(10):739-54. PMC: 4875349. DOI: 10.1007/s13238-012-2072-z. View

Pasut G, Veronese F . PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev. 2009; 61(13):1177-88. DOI: 10.1016/j.addr.2009.02.010. View

Pasut G, Veronese F . PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc). 2009; 45(9):687-95. DOI: 1396674/dot.2009.45.9.1416421. View

Strehlitz B, Reinemann C, Linkorn S, Stoltenburg R . Aptamers for pharmaceuticals and their application in environmental analytics. Bioanal Rev. 2012; 4(1):1-30. PMC: 3281204. DOI: 10.1007/s12566-011-0026-1. View

10.

Liu J, You M, Pu Y, Liu H, Ye M, Tan W . Recent developments in protein and cell-targeted aptamer selection and applications. Curr Med Chem. 2011; 18(27):4117-25. PMC: 5512708. DOI: 10.2174/092986711797189619. View

11.

Teissier E, Penin F, Pecheur E . Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules. 2011; 16(1):221-50. PMC: 6259279. DOI: 10.3390/molecules16010221. View

12.

Hatano H . Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 2013; 8(3):211-6. PMC: 4041488. DOI: 10.1097/COH.0b013e32835f9788. View

13.

Thiviyanathan V, Gorenstein D . Aptamers and the next generation of diagnostic reagents. Proteomics Clin Appl. 2012; 6(11-12):563-73. PMC: 4021847. DOI: 10.1002/prca.201200042. View

14.

Moebius U, Clayton L, Abraham S, Harrison S, Reinherz E . The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med. 1992; 176(2):507-17. PMC: 2119328. DOI: 10.1084/jem.176.2.507. View

15.

Zhang P, Zhao N, Zeng Z, Chang C, Zu Y . Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. Am J Clin Pathol. 2010; 134(4):586-93. DOI: 10.1309/AJCP55KQYWSGZRKC. View

16.

Zhao N, You J, Zeng Z, Li C, Zu Y . An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small. 2013; 9(20):3477-84. PMC: 3800505. DOI: 10.1002/smll.201202694. View

17.

Peeters M, Aghokeng A, Delaporte E . Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect. 2010; 16(10):1525-31. DOI: 10.1111/j.1469-0691.2010.03300.x. View

18.

Flores A, Quesada E . Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy. Curr Med Chem. 2013; 20(6):751-71. View

19.

Castro E, Belair M, Rizzardi G, Bart P, Pantaleo G, Graziosi C . Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-Linked glycosylation variants. AIDS Res Hum Retroviruses. 2008; 24(1):106-13. DOI: 10.1089/aid.2007.0139. View

20.

Hicke B, Marion C, Chang Y, Gould T, Lynott C, Parma D . Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem. 2001; 276(52):48644-54. DOI: 10.1074/jbc.M104651200. View